Prochoice Chrimatistiriaki Ltd Review

When FXCanary sets out to assess a broker, our first stop is always the public register of the regulator it claims – in this case, the Cyprus Securities and Exchange Commission (CySEC). We cross-reference the official domain against the licence details, check for clone warnings, and dig for any credible web footprint that confirms the entity is still actively serving traders. For Prochoice Chrimatistiriaki Ltd, that process revealed a mixed picture: the CySEC licence is genuine and has been active since 2009, but the firm’s online presence is so threadbare that we could not verify a functioning client-facing operation or a single independent user review.

We then broadened our search, looking for mentions in industry databases, broker comparison sites, and financial news. The results were sparse. What we did find – a basic company homepage, some third‑party profiles – added only a handful of details to the regulatory skeleton. No social media activity, no trading platform demos, no deposit or withdrawal information. This absence of transparency is itself a significant data point, and it shapes our assessment: an authorised broker that appears to have withdrawn from the public eye raises more questions than it answers.

In the following profile, we walk through everything we could substantiate, explain what CySEC regulation actually means for client money, and highlight the many gaps that a trader must confront before considering an account. Where facts are thin, we say so plainly – because for a cautious trader, what you don’t know can be more dangerous than what you do.

Prochoice Chrimatistiriaki Ltd is registered in Cyprus and operates under the trading name ProChoice stockbrokers, according to information aggregated from multiple industry databases. Its registered address is in Livadia, Larnaca, a town just outside the island’s financial hub. The company was granted its CySEC licence on 1 July 2009, making it a veteran of the post‑financial‑crisis regulatory era in Cyprus – a period when many brokers flocked to the jurisdiction for its EU passporting rights under the Markets in Financial Instruments Directive (MiFID).

Despite this longevity, the company’s public profile is almost nonexistent. Its official website, pro‑choice.com.cy, offers little more than a landing page with taglines like “the professional choice” and “Talk to the pros.” No detailed information about management, corporate history, or even a clear description of its services is provided. In an industry where trust is built on transparency, the lack of an “About Us” page or any executive bios is unusual and undermines confidence.

We also searched for any mention of the firm in financial news, press releases, or investor education content. Apart from its obligatory listing on the CySEC register, Prochoice appears to have left no public trail. For a broker that has been licensed for over 15 years, this silence is striking and suggests either a deliberate low‑profile strategy or a gradual scaling back of retail operations.

Prochoice Chrimatistiriaki Ltd holds a single Cyprus Investment Firm (CIF) licence, number 100/09, issued by the Cyprus Securities and Exchange Commission. Our check of the CySEC public register confirmed that the licence is currently authorised, meaning the firm has met the regulator’s ongoing compliance requirements and is permitted to provide investment services and activities. The licence covers reception and transmission of orders in relation to one or more financial instruments, as well as execution of orders on behalf of clients – essentially, the core functions of a brokerage.

The licence was granted in July 2009, placing Prochoice among the earlier wave of CySEC‑regulated firms. In the years since, CySEC has tightened its supervision, introducing stricter capital adequacy rules, leverage caps for retail clients, and mandatory participation in the Investor Compensation Fund (ICF). As an authorised firm, Prochoice falls under these protections, which we explain in the next section. However, it is important to note that the licence does not cover holding client money or dealing on own account unless explicitly stated – and from the available information, it appears Prochoice may only provide order execution and transmission services, though this is not entirely clear from the public record.

We found no evidence of any additional licences in other jurisdictions. The broker is not registered with the FCA in the UK, BaFin in Germany, or any other major European regulator outside Cyprus. This means that while it can passport its services across the EU under MiFID, it must notify each host regulator, and the level of direct oversight in those countries may be limited. For traders based outside Cyprus, this is a factor worth considering.

CySEC is a member of the European Securities and Markets Authority (ESMA) and operates within the harmonised EU regulatory framework. For retail traders, this translates into several concrete safeguards. First, client funds must be segregated from the firm’s own operational capital, held in separate accounts with reputable banks. If the broker becomes insolvent, these segregated accounts are ring‑fenced from creditors, and traders have a claim on their own money before the general liquidation process.

Second, all CySEC‑regulated firms are required to participate in the Investor Compensation Fund (ICF), which covers eligible retail clients up to €20,000 per claimant in the event that the broker fails and segregated funds are unrecoverable. While €20,000 is modest compared to some other jurisdictions, it provides a measurable safety net. However, eligibility and the claims process can be complex, and payouts are not guaranteed for all types of investment loss.

Third, under ESMA product intervention rules, CySEC enforces leverage limits on CFDs for retail clients: 30:1 for major currency pairs, 20:1 for minors and gold, and lower for other assets. It also mandates negative balance protection, meaning a client cannot lose more than their deposited funds. In addition, CySEC requires brokers to issue standardised risk warnings and restricts the marketing and distribution of CFDs to retail investors. These are robust protections that, in theory, make a CySEC licence a strong marker of safety.

However, the effectiveness of these protections depends entirely on the firm’s compliance and the regulator’s enforcement. CySEC has faced criticism in the past for being slow to act against misconduct. For a low‑visibility broker like Prochoice, where little public information exists, the practical application of these safeguards is harder to verify. Traders should therefore not take the licence alone as a blanket assurance.

One of the most fundamental pieces of information any trader needs before opening an account is what type of account they will get: what is the minimum deposit, what leverage applies, are there commission‑based or spread‑based options, and what execution model is used? For Prochoice, none of these details are available on its website. We checked the live site at pro‑choice.com.cy and found only a generic homepage with no links to account types, trading conditions, or a client portal.

Industry databases that aggregate broker data typically list multiple account tiers with corresponding minimum deposits and features. For Prochoice, even these third‑party sources draw a blank. One profile simply stated that the broker serves both retail and professional clients and offers order reception and execution, but gave no specifics on how those services differ between the two client categories. Professional clients, under ESMA rules, can request higher leverage but lose certain regulatory protections, so the absence of clear criteria is a serious shortcoming.

Because we cannot independently verify any account structure, we must conclude that the firm either does not actively advertise its services to retail traders or has simply not maintained its web presence. Either way, a trader cannot make an informed comparison or understand the costs before committing funds. In FXCanary’s assessment, this opacity is incompatible with the standard set by most CySEC‑regulated brokers, which present account comparisons as a matter of course.

A broker’s trading platform is the gateway to the markets, and most regulated firms proudly showcase their supported options – MetaTrader 4, MetaTrader 5, cTrader, or a proprietary web terminal. We searched Prochoice’s website and all available third‑party profiles for any indication of which platforms it offers. The result: complete silence. None of the partial screenshots or cached pages mention MT4, MT5, or any other platform. There is no download link, no user guide, and no demo account offer.

This is highly atypical for a CySEC‑regulated broker. Even if a firm provides only a basic web‑based interface or a white‑label solution, it would normally advertise that capability. The absence could mean one of several things: perhaps Prochoice operates purely as an introducing broker that passes orders to another execution venue without providing direct platform access; maybe it primarily serves institutional rather than retail clients; or perhaps the website is simply out of date and the platform is available only upon request. We contacted the firm via the phone number listed on some aggregator sites but received no response. Without a live demonstration or documented evidence, we cannot confirm that any functional trading platform exists for new clients.

For a trader, this is a critical red flag. A platform is not just a convenience; it is the tool through which you monitor the market, execute trades, and manage risk. Not knowing which platform you’ll be using – or whether one exists at all – makes it impossible to proceed with confidence. Even if the broker were to onboard you manually, the lack of transparency around the execution environment and platform features is a dealbreaker for many.

Despite the scarcity of official documentation, we were able to piece together a partial picture of Prochoice’s instrument offering from a broker profile on AllBrokerages.com, which cited information directly from the firm’s CySEC licence notification. According to that source, the broker provides access to forex, commodities, and indices, as well as equities listed on the Cyprus Stock Exchange and the Athens Stock Exchange. This suggests a product range that caters to both domestic investors interested in local shares and international traders looking for currency and commodity exposures.

The mention of equities is particularly interesting, as it hints at a possible stock‑broking heritage rather than a pure FX/CFD shop. Many older Cypriot investment firms started out offering execution on local bourses before expanding into global leveraged products. If Prochoice still maintains those direct market access (DMA) relationships for CSE and ASE equities, it could be a niche service for certain clients. However, we could find no live quotes, product schedule, or any trading specification that would allow a trader to understand spreads, contract sizes, or margin requirements for these instruments.

Commodities and indices typically imply CFDs, which are the standard contract form for speculative retail trading in Europe. Yet here again, the exact instruments, their tick sizes, and whether they are cash or futures‑based are all unknown. Without an official product disclosure or a terms‑of‑business document, any assumption about what you can actually trade with Prochoice is just speculation.

In the course of our research, we looked for any public information on minimum deposit, funding methods, withdrawal processing times, and non‑trading fees. We found none. The broker’s website contains no deposit or withdrawal page, no FAQ on payment methods, and no schedule of charges. Third‑party sites that usually collect such data from broker submissions or user reports have left the fields blank for Prochoice.

This black box presents a significant practical obstacle. A trader cannot know whether to expect a low minimum deposit of €100 or a more institutional‑level threshold of several thousand euros. There is no indication of whether bank wire, credit card, or e‑wallets are accepted, nor whether the broker charges for withdrawals or for account dormancy. In the absence of a client agreement or terms of business – which are not publicly hosted – the cost structure is effectively invisible.

For a CySEC‑regulated broker, this is non‑standard. The regulator expects firms to provide clients with pre‑contractual information that clearly outlines all costs and associated charges. While a firm may deliver such documents privately during onboarding, the lack of a public preview is a warning sign. It suggests either a deliberate attempt to avoid comparison shopping or an operational posture that is not geared toward self‑directed retail clients. Either way, it leaves the trader at a severe informational disadvantage.

Given the profile we have assembled, Prochoice might – and we stress might – be appropriate only for a very narrow segment of traders. Specifically, an existing professional or institutional client who has already been introduced to the firm through a personal relationship and can obtain the full suite of legal documents, platform demonstrations, and clear cost schedules directly from the management. For such a client, the CySEC licence provides a meaningful layer of oversight and compensation coverage that, combined with direct negotiation, could make the relationship workable.

For the vast majority of retail traders – especially those who are new to the markets – Prochoice is not suitable. The complete absence of public trading conditions, the unverifiable platform status, and the lack of independent user feedback create a risk profile that is simply too high. Day traders, scalpers, and algorithmic traders, who rely on precise execution and transparent fee structures, would find it impossible to evaluate the broker’s suitability without the missing data. Even a conservative long‑term investor interested in Cypriot equities would struggle to open an account without knowing the technology or the costs involved.

In FXCanary’s view, the threshold for trust should be much higher when a broker hides – deliberately or through neglect – the very information that allows a trader to make an informed decision. There are dozens of CySEC‑regulated brokers that offer full transparency: downloadable account tables, live platform demos, and detailed cost breakdowns. In comparison, Prochoice offers only a licence number and a phone number that rang unanswered.

FXCanary has assigned Prochoice Chrimatistiriaki Ltd a Scam Risk Score of 34 out of 100, which places it in our ‘Guarded’ category. This score is not a prediction of failure or fraud, but a quantitative reflection of the information gaps and warning signs we have identified. The core licence is real and has been maintained for over 15 years, which is a positive indicator – many scam operations do not survive this long under a recognised regulator. However, the near‑total absence of verifiable commercial activity, the non‑functional web presence, and the complete lack of user reviews weigh heavily against it.

The specific risk flag we raised – “No verifiable website or social‑media presence” – captures the essence of the problem. While a domain does exist, it offers no client utility, no disclosure, and no evidence that the firm is actively accepting new business. This is not the profile of a broker competing for customers in 2025; it is the profile of a company that may be in a wind‑down phase, operating solely as a legacy entity, or serving a closed circle of existing clients. Without clarity, the risk of onboarding frustration, lack of support, or even operational paralysis is high.

Our scoring methodology weights regulatory standing, transparency, user feedback, and market presence. Prochoice scores reasonably on the first, but fails on the latter three. For a trader, this translates into a broker that is legally authorised but practically opaque. In the highly competitive and trust‑dependent environment of online trading, opacity is a form of risk in itself.

If, despite our warnings, you are still considering Prochoice, we urge you to take a series of protective steps before depositing any money. First, contact CySEC directly or check the live register to confirm that licence number 100/09 remains authorised. Regulators occasionally suspend or withdraw licences, and the status can change without notice. Second, request in writing from the broker a full set of client onboarding documents, including the Customer Agreement, Best Execution Policy, Order Execution Policy, and a detailed schedule of all commissions, spreads, overnight swaps, and non‑trading fees. Compare these against the ESMA disclosure requirements to ensure completeness.

Next, demand a demo account or at least a walk‑through of the live platform to verify that it exists and functions properly. Test order execution on a small scale before committing serious capital. Be particularly wary of any request to send funds to bank accounts in a different name or jurisdiction; all transfers should go to a segregated client account held by Prochoice Chrimatistiriaki Ltd at a recognised bank. You can verify the account details with the bank directly if necessary.

Finally, maintain a healthy scepticism about any promises of high returns or exclusive market access. The most sophisticated frauds often hide behind a valid licence. Use the CySEC Investor Compensation Fund as a last‑resort safety net, but do not treat it as a substitute for due diligence – the claims process can be lengthy and success is never guaranteed. In the end, the best protection is to choose a broker that doesn’t make you guess about the safety and cost of your trades. On that score, Prochoice currently falls short.